WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H597162
CAS#: 163254-40-8 (sodium)
Description: levoleucovorin is the levo isomeric form of racemic d,l-leucovorin,. Levoleucovorin is the pharmacologically active isomer of leucovorin [(6-S)-leucovorin]. levoleucovorin is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid. levoleucovorin does not require reduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of “one-carbon” moieties. Administration of levoleucovorin can counteract the therapeutic and toxic effects of folic acid antagonists such as methotrexate, which act by inhibiting dihydrofolate reductase.levoleucovorin rescue is indicated after high-dose methotrexate therapy in osteosarcoma. levoleucovorin is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists.
Hodoodo Cat#: H597162
Name: Levoleucovorin disodium
CAS#: 163254-40-8 (sodium)
Chemical Formula: C20H21N7Na2O7
Exact Mass: 0.00
Molecular Weight: 517.410
Elemental Analysis: C, 46.43; H, 4.09; N, 18.95; Na, 8.89; O, 21.64
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 163254-40-8 (sodium) 80433-71-2 (calcium) 68538-85-2 (free acid)
Synonym: Levoleucovorin disodium; Disodium levofolinate;
IUPAC/Chemical Name: sodium (4-((((S)-2-amino-5-formyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl)methyl)amino)benzoyl)-L-glutamate
InChi Key: FSDMNNPYPVJNAT-NJHZPMQHSA-L
InChi Code: InChI=1S/C20H23N7O7.2Na/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30;;/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32);;/q;2*+1/p-2/t12-,13-;;/m0../s1
SMILES Code: O=C(CC[C@H](NC(C1=CC=C(C=C1)NC[C@@H]2N(C3=C(NC2)N=C(NC3=O)N)C=O)=O)C([O-])=O)[O-].[Na+].[Na+]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 517.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Leucovorin. 2023 Aug 15. PMID: 37247353.
2: Takada R, Ikezawa K, Yamai T, Watsuji K, Seiki Y, Kawamoto Y, Hirao T, Higashi S, Urabe M, Kai Y, Nakabori T, Uehara H, Kotani M, Yagi T, Kimura M, Nozaki K, Takagi M, Ohkawa K. Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer. BMC Cancer. 2023 Jul 31;23(1):711. doi: 10.1186/s12885-023-11205-6. PMID: 37518012; PMCID: PMC10388465.
3: Deshpande H. Levoleucovorin inhibits LOXL2 (lysyl oxidase like-2) to control breast cancer proliferation: a repurposing approach. J Biomol Struct Dyn. 2023 Jun 20:1-10. doi: 10.1080/07391102.2023.2224894. Epub ahead of print. PMID: 37340696.
4: Kobayashi S, Tezuka S, Yamachika Y, Tsunoda S, Nagashima S, Tozuka Y, Fukushima T, Morimoto M, Ueno M, Furuse J, Maeda S. FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study. BMC Cancer. 2023 Feb 21;23(1):177. doi: 10.1186/s12885-023-10654-3. PMID: 36809997; PMCID: PMC9945590.
5: Qiu B, Liu G, Wang C, Chen X, Liu R, Huang Y, Jia Y, Shen J. Three-Period Bioequivalence Study of Sodium Levofolinate Injection With Calcium Levofolinate for Injection and Sodium Folinate for Injection in Healthy Chinese Subjects. Clin Pharmacol Drug Dev. 2023 Apr;12(4):416-423. doi: 10.1002/cpdd.1223. Epub 2023 Feb 19. PMID: 36808267.
6: Su L, Zhao S, Yin Y, Huang F, Zhu J, Chen L; FNF Independent Investigations Group; Lin R. POF (paclitaxel/oxaliplatin/5-fluorouracil/leucovorin) vs. SOX/CAPOX/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer: Study protocol for a randomized controlled trial, FNF-014 trial. Front Med (Lausanne). 2022 Aug 2;9:861777. doi: 10.3389/fmed.2022.861777. PMID: 35983099; PMCID: PMC9380469.
7: Beaurain M, Rioufol C, Vantard N, Teixeira A, Baudouin A, Herledan C, Souquet PJ, Couraud S, Ranchon F. Intravenous route for folate supplementation in a patient with celiac disease treated by pemetrexed-based chemotherapy for non- small-cell lung cancer. J Oncol Pharm Pract. 2023 Apr;29(3):750-754. doi: 10.1177/10781552221117734. Epub 2022 Aug 2. PMID: 35918825.
8: Tam NM, Pham MQ, Ha NX, Nam PC, Phung HTT. Computational estimation of potential inhibitors from known drugs against the main protease of SARS-CoV-2. RSC Adv. 2021 May 12;11(28):17478-17486. doi: 10.1039/d1ra02529e. PMID: 35479689; PMCID: PMC9032918.
9: Kumar C, Lakshmi PTV, Arunachalam A. Computational investigation of FDA approved drugs as selective PARP-1 inhibitors by targeting BRCT domain for cancer therapy. J Mol Graph Model. 2021 Nov;108:107919. doi: 10.1016/j.jmgm.2021.107919. Epub 2021 Apr 6. PMID: 34304979.
10: Cirronis M, Novara E, Persiano T, Perlini S, Locatelli CA. Bowel perforation due to methotrexate therapeutic error: an insidious adverse reaction. Eur Rev Med Pharmacol Sci. 2021 Mar;25(5):2344-2347. doi: 10.26355/eurrev_202103_25273. PMID: 33755972.
11: Satake H, Ando K, Oki E, Shimokawa M, Makiyama A, Saeki H, Tsuji A, Mori M. Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer. BMC Cancer. 2020 Nov 17;20(1):1116. doi: 10.1186/s12885-020-07576-9. PMID: 33203393; PMCID: PMC7672899.
12: Peters GJ, van Gemert FPA, Kathmann I, Reddy G, Cillessen SAGM, Jansen G. Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro. Front Cell Dev Biol. 2020 Oct 9;8:577215. doi: 10.3389/fcell.2020.577215. PMID: 33163492; PMCID: PMC7581941.
13: Sanogo S, Silimbani P, Gaggeri R, Masini C. Stability of calcium levofolinate reconstituted in syringes and diluted in NaCl 0.9% and glucose 5% polyolefin/polyamide infusion bags. J Oncol Pharm Pract. 2021 Mar;27(2):288-296. doi: 10.1177/1078155220918025. Epub 2020 Apr 16. PMID: 32299315; PMCID: PMC7903855.
14: Mofidifar S, Sohraby F, Bagheri M, Aryapour H. Repurposing existing drugs for new AMPK activators as a strategy to extend lifespan: a computer-aided drug discovery study. Biogerontology. 2018 Apr;19(2):133-143. doi: 10.1007/s10522-018-9744-x. Epub 2018 Jan 15. PMID: 29335817.
15: Muto O, Munakata M, Yamagata K, Masuda A, Kotanagi K, Kichiraku T, Satoyoshi R, Kudoh K, Sawada T, Miyazawa H, Ouchi S, Kotanagi H, Sakata Y. Successful Treatment with 5-fluorouracil and Levofolinate Calcium in Advanced Gastric Cancer Patient with Disseminated Intravascular Coagulation. Gan To Kagaku Ryoho. 2017 Oct;44(10):867-869. PMID: 29066681.
16: Costa T, Nuñez J, Felismino T, Boente L, Mello C. REOX: Evaluation of the Efficacy of Retreatment With an Oxaliplatin-containing Regimen in Metastatic Colorectal Cancer: A Retrospective Single-center Study. Clin Colorectal Cancer. 2017 Dec;16(4):316-323. doi: 10.1016/j.clcc.2017.03.002. Epub 2017 Mar 16. PMID: 28392022.
17: Zhao R, Aluri S, Goldman ID. The proton-coupled folate transporter (PCFT- SLC46A1) and the syndrome of systemic and cerebral folate deficiency of infancy: Hereditary folate malabsorption. Mol Aspects Med. 2017 Feb;53:57-72. doi: 10.1016/j.mam.2016.09.002. Epub 2016 Sep 21. PMID: 27664775; PMCID: PMC5253092.
18: Roselli M, Formica V, Cereda V, Jochems C, Richards J, Grenga I, Orlandi A, Ferroni P, Guadagni F, Schlom J. The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy. Oncoimmunology. 2016 May 19;5(7):e1188243. doi: 10.1080/2162402X.2016.1188243. PMID: 27622042; PMCID: PMC5006891.
19: Lamberti M, Porto S, Zappavigna S, Stiuso P, Tirino V, Desiderio V, Mele L, Caraglia M. Levofolene modulates apoptosis induced by 5-fluorouracil through autophagy inhibition: clinical and occupational implications. Int J Oncol. 2015 May;46(5):1893-900. doi: 10.3892/ijo.2015.2904. Epub 2015 Feb 24. PMID: 25709090; PMCID: PMC4383012.
20: Wettergren Y, Taflin H, Odin E, Kodeda K, Derwinger K. A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study. Cancer Chemother Pharmacol. 2015 Jan;75(1):37-47. doi: 10.1007/s00280-014-2611-9. Epub 2014 Oct 24. PMID: 25342290; PMCID: PMC4281361.
